Overview

Nal-IRI/5-FU/LV Chemotherapy Combined with PD-L1 Inhibitor and Multi-target Anti-angiogenic Small MoleculeSBRT As Second-line Therapy in Metastatic Pancreatic Cancer Patients

Status:
NOT_YET_RECRUITING

Trial end date:
2027-12-01

Target enrollment:

Participant gender:

Summary

This study is a single-arm, multi-center, multi-cohort, prospective clinical study initiated by the investigator. The indication of this study is: patients with advanced metastatic pancreatic cancer who have progressed after first-line chemotherapy. Eligible patients will be assigned to liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU)/leucovorin (LV) (nal-IRI/5-FU/LV) combined with benmelstobart and anlotinib SBRT. The total sample size for this study is expected to be 56 subjects.

Phase:

PHASE2

Details

Lead Sponsor:

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Treatments:

anlotinib